Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 111Neoplasm Metastasis 9Neoplasms 5Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms, Male 3Breast Diseases 3Obesity 2Multiple Endocrine Neoplasia Type 1 2Endometrial Neoplasms 2Breast Cancer Metastatic 2Arthralgia 2Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Sleep Wake Disorders 1Skin Diseases 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Prostatic Neoplasms 1Primary Breast Cancer ER+ve 1Post Menopausal Women With Early Breast Cancer 1Patient Acceptance of Health Care 1Pain 1Ovarian Neoplasms 1Neoplasms by Site 1Metastatic Beast Cancer 1Mammary Neoplasms, Animal 1Lymphoma 1Lung Neoplasms 1Lung Diseases 1Lethal Congenital Contracture Syndrome 2 1

Interventions

seribantumab 2zenocutuzumab 1patritumab 1exemestane 1Vinorelbine 1Trastuzumab 1Letrozole 1In Situ Hybridization, Fluorescence 1Fulvestrant 1Erlotinib Hydrochloride 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lethal Congenital Contracture Syndrome 2 × exemestane × Clear all
NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Merus B.V.

Phase 2 Completed
105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡